D. Nagorney

Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum
20247 citationsauthor #9
Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy
20242 citationsauthor #12
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
20243 citationsauthor #12
Outcome comparisons of laparoscopic distal pancreatectomy vs open in pancreas cancer
20230 citationsauthor #11
Minimally invasive vs. open approach to the simultaneous treatment of colorectal tumors with synchronous liver metastasis: a single center, propensity-score matched analysis from Mayo clinic.
20233 citationsauthor #5
ASO Visual Abstract: Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases—Long-Term Follow-Up of Over 500 Patients
20232 citationsauthor #11
Stapled gastro-jejunostomy as a form of improved efficiency during whipple procedure
20230 citationsauthor #9
Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients
202332 citationsauthor #11
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection
20231 citationsauthor #14
ASO Author Reflections: Long-Term Outcomes after Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases
20230 citationsauthor #3
APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure-an international multicenter study of 14581 patients
20230 citationsauthor #24
Use of von Willebrand factor antigen for surgical decision making in patients with hepatocellular carcinoma
20230 citationsauthor #10
Should peritoneal metastases preclude cytoreductive hepatectomy for SINET liver metastases?
20231 citationsauthor #9
Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients
202336 citationsauthor #9
The utility of futility.
20230 citationsauthor #2
Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors
20225 citationsauthor #11
163: PANCREATIC NEUROENDOCRINE TUMORS – A DESCRIPTIVE STUDY OF A RECENT 12-YEAR SURGICAL RESECTION COHORT AT A TERTIARY INSTITUTION
20220 citationsauthor #7
ASO Visual Abstract: Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors
20220 citationsauthor #11
Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection.
202212 citationsauthor #4
Surgical Outcomes after Synchronous versus Metachronous Hepatectomy in Patients with Metastatic Pancreatic Neuroendocrine Tumors
20220 citationsauthor #7
Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous cystic lesions.
202212 citationsauthor #3
Solid Pseudopapillary Tumors of the Pancreas: Mayo Clinic 20 Years' Experience
20220 citationsauthor #6
Liver Transplantation with Concurrent Pancreatoduodenectomy for Hilar Cholangiocarcinoma with Common Bile Duct Involvement
20220 citationsauthor #5
Hepatobiliary and pancreatic resection for cholangiocarcinoma in patients with primary sclerosing cholangitis.
20220 citationsauthor #8
Hepatocellular carcinoma as predominant cancer subgroup accounting for sex differences in post-hepatectomy liver failure, morbidity and mortality.
20229 citationsauthor #9
Surgical and Oncologic Outcomes in Patients with BRAF-Mutated Colorectal Cancer Following Targeted Therapy and Hepatic Resection with Curative Intent
20220 citationsauthor #6
Is Pancreatectomy with Vascular Resection and Reconstruction for Locally Advanced Pancreatic Neuroendocrine Tumors Safe?
20220 citationsauthor #7
Laparoscopic Versus Open Liver Resections for Gallbladder Cancer and Intrahepatic Cholangiocarcinoma: The Mayo Clinic Experience
20220 citationsauthor #5
Laparoscopic versus open liver resections for intrahepatic cholangiocarcinoma and gallbladder cancer: the Mayo clinic experience.
202210 citationsauthor #3
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
202251 citationsauthor #18
Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance
20224 citationsauthor #11
Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer.
202213 citationsauthor #13
Laparoscopic liver resections for gallbladder cancer and intrahepatic cholangiocarcinoma: the Mayo clinic experience
20210 citationsauthor #2
Combined APRI/ALBI score to predict mortality after hepatic resection
202130 citationsauthor #5
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
202161 citationsauthor #15
Hepatic Venous Outflow Obstruction in Polycystic Liver Disease
20210 citationsauthor #6
Cholangiocarcinoma with an FGFR2 phenotype: outcomes in patients following surgical resection
20210 citationsauthor #4
Abstract 413: Preclinical efficacy of platinum based chemotherapy regimens and targeted therapeutics in the first successful described patient derived xenograft model of mixed acinar neuroendocrine carcinoma of the pancreas
20210 citationsauthor #8
Outcomes of pancreatectomy with portomesenteric venous resection and reconstruction for locally advanced pancreatic neuroendocrine neoplasms.
20215 citationsauthor #8
Doubling Time of Residual Tumor Volume for Metastatic Neuroendocrine Tumors Determines Survival Outcomes after Hepatic Resection
20211 citationsauthor #6
Sa304 METHYLATED DNA MARKERS IN TISSUE FROM SURGICALLY RESECTED INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS DETECT HIGH-GRADE DYSPLASIA WITH OR WITHOUT INVASIVE CANCER IN THE FIELD
20210 citationsauthor #15
Surgical and reconstructive outcomes in primary venous leiomyosarcoma.
20213 citationsauthor #8
Corrigendum to: Ingested fishbone causing a hepatic abscess.
20210 citationsauthor #3
Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous lesions
20210 citationsauthor #6
ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
20210 citationsauthor #15
Synchronous resection of colorectal cancer primary and liver metastases: an outcomes analysis.
202124 citationsauthor #7
Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinical Trial.
202110 citationsauthor #9
Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors
20217 citationsauthor #7
Neoadjuvant chemotherapy switch allows for surgical salvage in borderline & locally advanced pancreatic cancer
20211 citationsauthor #9
Curative intent resections for cholangiocarcinoma in primary sclerosing cholangitis (PSC) patients: the Mayo Clinic experience
20210 citationsauthor #5
Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspiration.
20213 citationsauthor #9
Improved outcome of women after liver resection is predominantly hepatocellular carcinoma dependent
20210 citationsauthor #4
A national database analysis of acinar cell carcinoma of the pancreas, a histologically, epidemiologically, and biologically distinct entity increasing in incidence
20214 citationsauthor #10
"Answers in hours": A prospective clinical study using nanopore sequencing for bile duct cultures.
202114 citationsauthor #12
Synchronous colorectal liver metastases: therapeutic considerations.
20217 citationsauthor #3
Perception versus reality: A National Cohort Analysis of the surgery‐first approach for resectable pancreatic cancer
20214 citationsauthor #11
Surgical management of intrahepatic cholangiocarcinoma: The mayo experience
20200 citationsauthor #9
Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery
202015 citationsauthor #13
Emergent pancreatectomy for neoplastic disease: outcomes analysis of 534 ACS-NSQIP patients
20209 citationsauthor #9
Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma.
202010 citationsauthor #7
En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent.
202064 citationsauthor #4
Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.
202014 citationsauthor #7
Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
202042 citationsauthor #8
Current Indications and Long-Term Outcomes of Surgical Portosystemic Shunts in Adults
20205 citationsauthor #4
Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
202034 citationsauthor #8
Is mandatory routine caudate lobe resection indicated in hilar cholangiocarcinoma ?
20203 citationsauthor #9
Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
202020 citationsauthor #11
Outcomes Following Synchronous Resection Of Colorectal Cancer Primary And Liver Metastases
20200 citationsauthor #6
Finding the Balance: General Surgery Resident Versus Fellow Training and Exposure in Hepatobiliary and Pancreatic Surgery.
20205 citationsauthor #7
Neoadjuvant chemotherapy followed by liver resection for patients with metastatic colorectal cancer.
20200 citationsauthor #4
Portomesenteric venous complications following pancreatic resection: toward development of a clinical scoring system to predict incidence, sequelae and management
20190 citationsauthor #8
Splenectomy for Conditions Other Than Trauma
20195 citationsauthor #3
FRI-365-Efficacy of combined partial hepatectomy and cyst fenestration on health-related quality of life in polycystic liver disease
20190 citationsauthor #5
Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis
201942 citationsauthor #6
Indocyanine green fluorescent imaging in revisional laparoscopic portal node dissection and liver resection following incidental finding of gallbladder adenocarcinoma after cholecystectomy
20190 citationsauthor #4
Laparoscopic distal pancreatectomy provides equivalent oncologic outcomes compared to open approaches for patients with pancreatic ductal adenocarcinoma
20190 citationsauthor #6
Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer?
20192 citationsauthor #2
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for nced Pancreatic Cancer
20191 citationsauthor #3
Current clinical indications and midterm outcomes of surgical portosystemic shunts in adults
20190 citationsauthor #4
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
2019335 citationsauthor #3
Preoperative opioid use is associated with increased length of stay after pancreaticoduodenectomy.
20195 citationsauthor #9
Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features.
2019111 citationsauthor #7
Portal Hypertension
20190 citationsauthor #2
Acinar cell carcinoma of the pancreas: increasing incidence, improved survival
20190 citationsauthor #7
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease
20195 citationsauthor #14
Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
201915 citationsauthor #5
Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens
201924 citationsauthor #7
How I Treat Oligometastatic Colorectal Cancer Through Surgery
20190 citationsauthor #2
Readmissions after pancreatic and liver surgery
20190 citationsauthor #9
Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study).
201836 citationsauthor #8
Portomesenteric venous complications following pancreatoduodenectomy: incidence and risk factors
20180 citationsauthor #6
Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection.
2018102 citationsauthor #5
Does additional re-resection of a positive proximal margin in hilar cholangiocarcinoma affect survival? Mayo experience
20180 citationsauthor #5
Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.
201818 citationsauthor #2
Comprehensive Characterization of Cancer Driver Genes and Mutations
20181,913 citationsauthor #464
Laparoscopic pancreatoduodenectomy for patients with borderline resectable pancreatic ductal adenocarcinoma: feasibility and outcomes
20180 citationsauthor #5
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience.
201816 citationsauthor #9
Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty‐nine patients
201812 citationsauthor #7
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
20182,523 citationsauthor #460
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context
2018229 citationsauthor #438

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT